Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy.

Gremmel T, Perkmann T, Seidinger D, Koppensteiner R, Panzer S, Kopp CW, Steiner S.

J Atheroscler Thromb. 2013;20(7):630-45. Epub 2013 Jun 4.

2.

Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Platelets. 2011;22(3):188-95. doi: 10.3109/09537104.2010.543963. Epub 2011 Jan 13.

PMID:
21231857
3.

Response to antiplatelet therapy is independent of endogenous thrombin generation potential.

Gremmel T, Panzer S, Steiner S, Seidinger D, Koppensteiner R, Pabinger I, Kopp CW, Ay C.

Thromb Res. 2013 Jul;132(1):e24-30. doi: 10.1016/j.thromres.2013.04.008. Epub 2013 Apr 25.

PMID:
23623170
4.

Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.

Larsen SB, Grove EL, Kristensen SD, Hvas AM.

Thromb Haemost. 2013 May;109(5):920-9. doi: 10.1160/TH12-09-0666. Epub 2013 Feb 14.

PMID:
23407706
5.

Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.

Gremmel T, Koppensteiner R, Panzer S.

PLoS One. 2015 Jun 9;10(6):e0129666. doi: 10.1371/journal.pone.0129666. eCollection 2015.

6.

Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.

Kapłon-Cieślicka A, Rosiak M, Postuła M, Serafin A, Kondracka A, Opolski G, Filipiak KJ.

Kardiol Pol. 2013;71(9):893-902. doi: 10.5603/KP.2013.0055.

7.

Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.

Temperilli F, Rina A, Massimi I, Montemari AL, Guarino ML, Zicari A, Pulcinelli FM.

Platelets. 2015;26(8):783-7. doi: 10.3109/09537104.2014.1003291. Epub 2015 Mar 3.

PMID:
25734355
8.

Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.

Liu T, Zhang J, Chen X, Feng X, Fu SW, McCaffrey TA, Liu M.

Gene. 2015 Oct 15;571(1):23-7. doi: 10.1016/j.gene.2015.06.045. Epub 2015 Jun 19.

PMID:
26095809
9.

Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.

Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R.

Thromb Haemost. 2010 Aug;104(2):287-92. doi: 10.1160/TH09-12-0832. Epub 2010 May 10.

PMID:
20458439
10.

Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.

Good RI, McGarrity A, James TE, Miller H, McConnachie A, Goodall AH, Oldroyd KG.

Thromb Res. 2015 Jun;135(6):1140-6. doi: 10.1016/j.thromres.2015.02.021. Epub 2015 Feb 26.

PMID:
25746368
11.

A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.

Carroll RC, Craft RM, Snider CC, Aligeti VR, Wortham DC.

Anesth Analg. 2013 Feb;116(2):282-6. doi: 10.1213/ANE.0b013e318277de06. Epub 2013 Jan 9.

PMID:
23302970
12.

Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.

Gremmel T, Müller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, Panzer S.

Nephrol Dial Transplant. 2013 Aug;28(8):2116-22. doi: 10.1093/ndt/gft103. Epub 2013 May 31.

PMID:
23729489
13.

The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2011 Oct;128(4):352-7. doi: 10.1016/j.thromres.2011.05.008. Epub 2011 May 28.

PMID:
21621250
14.

Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).

Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG.

Thromb Haemost. 2009 Aug;102(2):404-11. doi: 10.1160/TH09-02-0126.

PMID:
19652893
15.

Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance.

Gillet B, Ianotto JC, Mingant F, Didier R, Gilard M, Ugo V, Lippert E, Galinat H.

Thromb Res. 2016 Jun;142:26-32. doi: 10.1016/j.thromres.2016.04.006. Epub 2016 Apr 14.

PMID:
27105311
16.

Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.

Guthikonda S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, Dong JF, Lev EI, Kleiman NS.

Thromb Haemost. 2008 Jul;100(1):83-9. doi: 10.1160/TH07-10-0590.

PMID:
18612542
17.

Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.

Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS).

Cardiovasc Drugs Ther. 2015;29(5):443-50. doi: 10.1007/s10557-015-6616-3.

PMID:
26428927
18.
19.

Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Haemost. 2009 Feb;101(2):333-9.

PMID:
19190818
20.

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG.

Eur Heart J. 2007 Jul;28(14):1702-8. Epub 2007 Jun 14.

PMID:
17569678

Supplemental Content

Support Center